Coultreon Biopharma
Immunology & Inflammation Therapeutics · Biotechnology
$125Mlatest round · Series A · Apr 2026 · 6 mo ago
1backers · Sofinnova Investments
50+team · employees, estimated range
12stories in the press
Overview
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune disease. Our pipeline targets SIK3 to deliver transformative therapies where unmet need remains high.
Key facts
These are the key facts about Coultreon Biopharma on Alion as of Nov 13, 2026. Coultreon Biopharma is headquartered in Leuven, Belgium. The latest round is Series A of $125M, announced in 2026.
- Headquarters
- Leuven, BelgiumAlion company profile, updated Oct 27, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $125MSum of 1 equity round Alion knows
- Latest round
- Series A · $125M · Apr 28, 2026Press report · finanznachrichten.de
Funding and backers
Total raised
$125M
1 round on record
Latest round
$125M
Series A · Apr 2026 · 6 mo ago
Team
51-200
employees, estimated range
Backers
1
Sofinnova Investments
The money's age
Fresh money
6 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 18
New executive Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer · The Manila Times
Apr 28
Raised a round Series A $125M · led by Sofinnova Investments · FinanzNachrichten.de
Apr 2026
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Apr 2026 | $125M | Sofinnova Investments lead, Novo Holdings Proceeds lead | FinanzNachrichten.de |
Founders and leadersfrom filings, registers and the company's site
Pierre RaboissonDirectorscompany's site
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Elevara Medicines is a clinical-stage biotech. ELV001 targets fibroblast-like synoviocytes and synergizes with DMARDs to achieve clinical…
Boomerang Medical is a bioelectronic medicine company targeting autoimmune diseases.
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
About Elpiscience is a clinical-stage biopharmaceutical company dedicated to the development of innovative immunotherapies for oncology and…
Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell…
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Financials
Total raised
$125M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2026 | $125M | Details |
People
Pierre Raboisson
Directors
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Sofinnova InvestmentsVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
Nate Massari's business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis...
Read more
Report
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
Nate Massari's business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn's disease, will support the advancement of Coultreon
Read more
Report
Coultreon Biopharma BV: Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
Nate Massari's business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn's disease, will support the advancement of Coultreon's
Read more
Report
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
Dr. Charuworn's extensive immunology drug development experience will help accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671
Read more
Report
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
Dr. Charuworn's extensive immunology drug development experience will help accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026. Coultreon Biopharma, a clinical-stage biotechnology comp
Read more
Report
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
Dr. Charuworn's extensive immunology drug development experience will help accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026. Coultreon Biopharma, a clinical-stage biotechnology comp
Read more
Report
Coultreon Biopharma BV: Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
Dr. Charuworn's extensive immunology drug development experience will help accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026.
Read more
Report
Coultreon Biopharma Raises $125 Million Series A to Advance Oral Autoimmune Therapy
Coultreon Biopharma, a Belgium-based biotechnology company formerly known as Onco3R Therapeutics, has closed an oversubscribed 125 million dollar Series A financing round to advance its immunology pipeline. The round was led by Sofinnova Investments and c
Read more
Report
Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipeline
Financing led by Sofinnova Investments and co-led by Forbion and Novo Holdings
Read more
Report
Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipeline
Financing led by Sofinnova Investments and co-led by Forbion and Novo Holdings Proceeds to advance lead immunology program COL-5671, a potential first-in-class, oral once-daily therapy, across a range of auto-immune indications Leuven, Belgium. April 28,
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Leuven
Belgium
HQ
50-200 est. staff
Gaston Geenslaan 3, Leuven, 3001, BE
How to cite this page
Alion, "Coultreon Biopharma: key facts", as of Nov 13, 2026. https://alion.io/company/coultreon
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0